GlassScriptPhysician profile
Sudhir Gosain
NPI 1891709226
$59,889.60
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $4,689 · 2021: $2,820 · 2022: $250.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $39,956.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,302.08 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $2,150.00 | 2020 | |
| Genzyme Corporation | $196.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $94.12 | 2021 | |
| Amgen INC. | $94.12 | 2021 | |
| Organogenesis INC. | $35.04 | 2019-2021 | |
| Baxter Healthcare | $23.98 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.81 | 2021 | |
| Polarityte, INC. | $14.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhir Gosain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.